<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>59</patient-age><report-id>PHHY2012FR110136</report-id><gender>male</gender><reactions><reaction>Left hemiplegia with aphasia</reaction><reaction>Aphasia</reaction><reaction>Transient ischaemic attack</reaction><reaction>Worsening of atrial fibrillation</reaction><reaction>Arterial hypotension</reaction><reaction>Hypomagnesemia/ 0.64 (unit not provided)</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>NISISCO</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hypertension</indication></indications><patient-age>59</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053096_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133609</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012FR110136</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-28</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-11-28</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012FR110136</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>59</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tobacco user</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Asthma</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Crohn's disease</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Left hemiplegia with aphasia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Left hemiplegia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hemiplegia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Aphasia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Aphasia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Aphasia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Transient ischaemic attack</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Transient ischaemic attack</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Transient ischaemic attack</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121104</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Worsening of atrial fibrillation</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Atrial fibrillation aggravated</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Atrial fibrillation</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121104</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Arterial hypotension</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arterial hypotension</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypotension</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121104</reactionstartdate>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypomagnesemia/ 0.64 (unit not provided)</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypomagnesemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypomagnesaemia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121104</testdate>
				<testname>Blood magnesium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121104</testdate>
				<testname>Troponin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NISISCO</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>20-818</drugauthorizationnumb>
				<drugauthorizationcountry>FR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>1 DF (160mg vals, 25 mg HCT), daily</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-04</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>VALSARTAN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Aphasia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Aphasia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Atrial fibrillation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Atrial fibrillation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hemiplegia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hemiplegia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypomagnesaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypomagnesaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypotension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transient ischaemic attack</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Transient ischaemic attack</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012FR110136, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">other health care professional </Semaphore><Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">via <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>Health </Semaphore>Authority (CRPV of NICE file NC20120839) forwarded by IPSEN BEAUFOUR on 28 Nov 2012, with follow up from other healthcare <Semaphore x="2231196" class="Occupation" value="Miscellaneous Occupation" score="0.58" ID="C20192">professional </Semaphore>received on 28 Nov 2012. This report refers to a 59-year old male patient. The patient had medical history of <Semaphore x="1550634" class="Disease or Finding" value="Asthma" score="1.00" ID="C28397">asthma</Semaphore>, <Semaphore x="1822626" class="Disease or Finding" value="Crohn Disease of Small Intestine" score="1.00" ID="C35210">crohnâ€™s disease </Semaphore>and was <Semaphore x="3280826" class="MedDRA LLT" value="Tobacco user" score="1.00" ID="10057581">tobacco user</Semaphore>. The patient received Nisisco (valsartan/hydrochlorothiazide) 160/25 mg tablet <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypertension </Semaphore>from unknown date at the dose of 1 DF daily. On 4 Nov 2012, he was hospitalized for <Semaphore x="2996534" class="MedDRA LLT" value="Hemiplegia" score="1.00" ID="10019468">left <Semaphore x="2014197" class="Disease or Finding" value="Hemiplegia" score="1.00" ID="C64329">hemiplegia </Semaphore></Semaphore>with <Semaphore x="1536951" class="Disease or Finding" value="Aphasia" score="1.00" ID="C34393">aphasia </Semaphore>and he spontaneously recovered. On emergency unit, <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigations </Semaphore>was performed and his <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">blood pressure </Semaphore>was at 117/92, <Semaphore x="3289208" class="MedDRA LLT" value="Troponin" score="1.00" ID="10061576">troponin </Semaphore>was at 1.19, <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">haemoglobin </Semaphore>(Hb) was at 17.7 mg/dL, and <Semaphore x="2812633" class="MedDRA LLT" value="Blood magnesium" score="1.00" ID="10005651">Magnesium </Semaphore>(Mg) was at 0.64 (unit not provided) showing <Semaphore x="3021789" class="MedDRA LLT" value="Hypomagnesaemia" score="1.00" ID="10021027">hypomagnesaemia </Semaphore>which could have taken part in the worsening of <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation</Semaphore>. A <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnostic </Semaphore>of <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">transient ischemic attack </Semaphore>on <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>and with <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>was <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">made</Semaphore>. After <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>of <Semaphore x="3285702" class="MedDRA LLT" value="Transient ischaemic attack" score="1.00" ID="10044390">transient ischaemic attack </Semaphore>on <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>with <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension</Semaphore>, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="3295113" class="MedDRA LLT" value="Underweight" score="1.00" ID="10048828">low molecular weight </Semaphore><Semaphore x="658468" class="Medicine" value="Heparin" score="0.49" ID="269926">heparin </Semaphore>(LMWH) was started. Nisisco was discontinued on 04 Nov 2012 and switched for ARA2 (Aprovel) 75 mg daily. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the <Semaphore x="2996534" class="MedDRA LLT" value="Hemiplegia" score="1.00" ID="10019468">left <Semaphore x="2014197" class="Disease or Finding" value="Hemiplegia" score="1.00" ID="C64329">hemiplegia </Semaphore>with <Semaphore x="1536951" class="Disease or Finding" value="Aphasia" score="1.00" ID="C34393">aphasia</Semaphore><Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">, <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">transient </Semaphore></Semaphore></Semaphore>
    <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">
     <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">
      <Semaphore x="3285702" class="MedDRA LLT" value="Transient ischaemic attack" score="1.00" ID="10044390">
       <Semaphore x="2640323" class="Procedure" value="Transient Ischemic Dilation" score="1.00" ID="C94996">
        <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">ischemic attack</Semaphore></Semaphore></Semaphore></Semaphore>, </Semaphore><Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>and <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore><Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>was reported as <Semaphore x="1803876" class="Disease or Finding" value="Complete Recovery" score="1.00" ID="C82467">complete recovery</Semaphore>; whereas <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="3021789" class="MedDRA LLT" value="Hypomagnesaemia" score="1.00" ID="10021027">hypomagnesaemia </Semaphore>was not reported. The <Semaphore x="1947545" class="Race" value="French" score="1.00" ID="C43854">French </Semaphore>Health Authority considered the events left <Semaphore x="2014197" class="Disease or Finding" value="Hemiplegia" score="1.00" ID="C64329">hemiplegia </Semaphore>with <Semaphore x="1536951" class="Disease or Finding" value="Aphasia" score="1.00" ID="C34393">aphasia </Semaphore>and <Semaphore x="2640289" class="Disease or Finding" value="Transient Ischemic Attack" score="1.00" ID="C50781">transient ischemic attack </Semaphore>whereas seriousness of the event <Semaphore x="3021789" class="MedDRA LLT" value="Hypomagnesaemia" score="1.00" ID="10021027">hypomagnesaemia</Semaphore>, <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>and <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arterial </Semaphore><Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypotension </Semaphore>was not reported. The Health Authority assessed causality of the events as suspected and commented that the events dubiously related to Nisisco <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>.Follow up received on 28 Nov 2012: Updated historical condition <Semaphore x="3280826" class="MedDRA LLT" value="Tobacco user" score="1.00" ID="10057581">tobacco user </Semaphore>and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>.</narrativeincludeclinical>
				<sendercomment>
Based on  Review of available reported data does not allow for a proper causality assessment. Reported event(s) is (are) unassessable</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>